Aminoglycosides and uses thereof in treating genetic disorders

Patent metadata

Field	Value
Publication number	US-9616079-B2
Application number	US-201514866960-A
Country	US
Kind code	B2
Filing date	Sep 27, 2015
Priority date	Nov 18, 2010
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I:

or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.

First claim

What is claimed is:

1. A method for increasing the expression level of a gene having a premature stop-codon mutation, the method comprising translating the gene into a protein in the presence of a compound represented by general Formula I:

or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is selected from the group consisting of alkyl, cycloalkyl and aryl;
R 2 is hydrogen or (S)-4-amino-2-hydroxybutyryl (AHB);
R 3 is selected from the group consisting of hydrogen, alkyl, cycloalkyl and aryl; and
a stereo-configuration of each of position 6′ and position 5″ is independently an R configuration or an S configuration,
so as to readthrough said stop-codon, thereby increasing the expression level of the gene.

2. The method of claim 1 , wherein said premature stop-codon mutation has an RNA code selected from the group consisting of UGA, UAG and UAA.

3. The method of claim 1 , wherein said protein is translated in a cytoplasmic translation system.

4. The method of claim 1 , wherein said compound is present in a mutation suppression amount.

5. The method of claim 1 , wherein an inhibition of translation IC 50 of said compound in a eukaryotic cytoplasmic translation system is greater that an inhibition of translation IC 50 of said compound in a ribosomal translation system.

6. The method of claim 1 , wherein an inhibition of translation IC 50 of said compound in a eukaryotic cytoplasmic translation system is greater that an inhibition of translation IC 50 of said compound in a prokaryotic translation system.

7. The method of claim 1 , wherein R 1 is alkyl.

8. The method of claim 7 , wherein said alkyl is methyl.

9. The method of claim 1 , wherein R 2 and R 3 are each hydrogen.

10. The method of claim 1 , wherein R 2 is AHB and R 3 is hydrogen.

11. The method of claim 1 , wherein R 2 is hydrogen and R 3 is alkyl.

12. The method of claim 1 , wherein R 2 is AHB and R 3 is alkyl.

13. The method of claim 12 , wherein said alkyl is methyl.

14. The method of claim 1 , wherein said compound is selected from the group consisting of:

Assignees

• Technion Res & Dev Foundation

Inventors

• Baasov Timor
• Atia-Glikin Dana
• Kandasamy Jeyakumar
• Belakhov Valery

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A61P13/12

  of the kidneys · CPC title

• A61P21/04

  for myasthenia gravis · CPC title